Abstract
Typically the normal epithelial cells are a single layer, held tightly by adherent proteins that prevent the mobilization of the cells from the monolayer sheet. During prostate cancer progression, the epithelial cells can undergo epithelial-mesenchymal transition or EMT, characterized by morphological changes in their phenotype from cuboidal to spindle-shaped. This is associated with biochemical changes in which epithelial cell markers such as E-cadherin and occludins are down-regulated, which leads to loss of cell-cell adhesion, while mesenchymal markers such as vimentin and N-cadherin are up-regulated, thereby allowing the cells to migrate or metastasize to different organs. The EMT transition can be regulated directly and indirectly by multiple molecular mechanisms including growth factors and cytokines such as transforming growth factor-beta (TGF-β), epidermal growth factor (EGF) and insulin-like growth factor (IGF), and signaling pathways such as mitogen-activated protein kinase (MAPK) and Phosphatidylinositol 3-Kinase (PI3K). This signaling subsequently induces expression of various transcription factors like Snail, Twist, Zeb1/2, that are also known as master regulators of EMT. Various markers associated with EMT have been reported in prostate cancer patient tissue as well as a possible association with health disparities. There has been consideration to therapeutically target EMT in prostate cancer patients by targeting the EMT signaling pathways.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14(6):818–829
Thiery JP et al (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420
Imran Khan M et al (2015) Role of epithelial mesenchymal transition in prostate tumorigenesis. Curr Pharm Des 21(10):1240–1248
Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454
Micalizzi DS, Farabaugh SM, Ford HL (2010) Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 15(2):117–134
Nauseef JT, Henry MD (2011) Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 8(8):428–439
Radisky DC (2005) Epithelial-mesenchymal transition. J Cell Sci 118(19):4325–4326
Nieto MA, Cano A (2012) The epithelial–mesenchymal transition under control: global programs to regulate epithelial plasticity. In Seminars in cancer biology. Elsevier
Sethi S et al (2011) Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3(1):90
Harris WP et al (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6(2):76–85
Grant CM, Kyprianou N (2013) Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. Translational andrology and urology 2(3):202
Liu Y-N et al (2008) Activated androgen receptor downregulates E-cadherin gene expression and promotes tumor metastasis. Mol Cell Biol 28(23):7096–7108
Cano A et al (2000) The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2(2):76
Nieto MA (2002) The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3(3):155–166
Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428
Smith BN, Odero-Marah VA (2012) The role of snail in prostate cancer. Cell Adhes Migr 6(5):433–441
Zhau HE et al (2008) Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25(6):601
Thakur N, Gudey S, Marcusson A, Fu J, Bergh A, Heldin C, Landstrom M (2014) TGF-ß-induced invasion of prostate Cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1. Cell Cycle 13(15):2400–2414
Tu WH et al (2003) The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 5(3):267–277
Cao Z, Kyprianou N (2015) Mechanisms navigating the TGF-ß pathway in prostate cancer. Asian J Urol 2:11–18
Gennigens C, Menetrier-Caux C, Droz JP (2006) Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 58(2):124–145
Graham TR et al (2008) Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 68(7):2479–2488
Di Lorenzo G et al (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8(11):3438–3444
Tang J et al (2016) CX3CL1 increases invasiveness and metastasis by promoting epithelial-to-mesenchymal transition through the TACE/TGF-alpha/EGFR pathway in hypoxic androgen-independent prostate cancer cells. Oncol Rep 35(2):1153–1162
Grotzinger J (2002) Molecular mechanisms of cytokine receptor activation. Biochim Biophys Acta 1592(3):215–223
Maruyama IN (2014) Mechanisms of activation of receptor tyrosine kinases: monomers or dimers. Cell 3(2):304–330
Hughes FJ et al (2006) Effects of growth factors and cytokines on osteoblast differentiation. Periodontol 2000 41:48–72
Poniatowski LA et al (2015) Transforming growth factor Beta family: insight into the role of growth factors in regulation of fracture healing biology and potential clinical applications. Mediat Inflamm 2015:137823
Akhurst RJ, Derynck R (2001) TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol 11(11):S44–S51
Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19(2):156–172
Cho KH et al (2014) A ROS/STAT3/HIF-1alpha signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion. Prostate 74(5):528–536
Gravdal K et al (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13(23):7003–7011
Sethi S et al (2010) Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res 3(1):90–99
Miller DB (2014) Pre-screening age African-American males: what do they know about prostate cancer screening, knowledge, and risk perceptions? Soc Work Health Care 53(3):268–288
Wang H et al (2016) Kaiso, a transcriptional repressor, promotes cell migration and invasion of prostate cancer cells through regulation of miR-31 expression. Oncotarget 7(5):5677–5689
Li P, Yang R, Gao W-Q (2014) Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer 13(1):55
Makrilia N et al (2009) Cell adhesion molecules: role and clinical significance in cancer. Cancer Investig 27(10):1023–1037
Cao Z et al (2017) Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. Oncotarget 8(45):78507–78519
Ping H et al (2016) IKK inhibitor suppresses epithelial-mesenchymal transition and induces cell death in prostate cancer. Oncol Rep 36(3):1658–1664
Qu X et al (2017) Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy. Oncotarget 8(17):29501–29518
Jones E, Pu H, Kyprianou N (2009) Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 13(2):227–234
Burton LJ et al (2014) Muscadine grape skin extract reverts snail-mediated epithelial mesenchymal transition via superoxide species in human prostate cancer cells. BMC Complement Altern Med 14:97
Hudson TS et al (2007) Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms. Cancer Res 67(17):8396–8405
Paller CJ et al (2015) A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: safety, tolerability, and dose determination. Prostate 75(14):1518–1525
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Odero-Marah, V., Hawsawi, O., Henderson, V., Sweeney, J. (2018). Epithelial-Mesenchymal Transition (EMT) and Prostate Cancer. In: Schatten, H. (eds) Cell & Molecular Biology of Prostate Cancer. Advances in Experimental Medicine and Biology, vol 1095. Springer, Cham. https://doi.org/10.1007/978-3-319-95693-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-95693-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95692-3
Online ISBN: 978-3-319-95693-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)